



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Michl et al.

Examiner: Unassigned

Serial No.: 10/542,239

Group: Unassigned

Filed: July 15, 2005

Docket: 1181-8 PCT US

Corresponding to:

Dated: October 14, 2005

International Patent Application
PCT/US2004/001196

International Filing Date: 16 January 2004

**For: PANCREATIC CANCER ASSOCIATED
ANTIGEN, ANTIBODY THERETO, AND
DIAGNOSTIC AND TREATMENT METHODS**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Pursuant to Applicants duty of disclosure, the information listed in the attached Form PTO-1449 is brought to the attention of the Examiner.

The citation of the listed item is not a representation that it constitutes a complete or exhaustive listing of the relevant art or that the reference is prior art. The item listed is submitted in good faith, but is not intended to substitute for the Examiner's search. It is hoped,

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to the: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 14, 2005.

Dated: October 14, 2005


Ann R. Pokalsky

The PTO did not receive the following
listed item(s) the reference list
in Form 1449.

however, that in addition to apprising the Examiner of this particular item, it will assist in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Also submitted herewith is a copy of the International Search Report issued in the corresponding PCT application, of which the above-identified application is a section 371 application. The item listed in the Form PTO -1449 submitted herewith is the only item listed in the International Search Report.

Inasmuch as this Information Disclosure Statement is being filed no more than three months from the filing date of the application, no fee is due.

Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 04-1121. Also, in the event any extensions of time for responding and/or a petition under 37 C.F.R. §1.17(i)(i) are required for the pending application(s), please treat this paper as a petition to extend the time and/or enter this Information Disclosure Statement as required and charge Deposit Account No. 04-1121 therefor. TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.

The claims of the application as now presented are believed to be patentably distinguishable over the prior art and to be in condition for allowance. Early and favorable

consideration of the case is respectfully requested.

Respectfully submitted,



Ann R. Pokalsky
Registration No.: 34,697
Attorney for Applicants

DILWORTH & BARRESE, LLP
333 Earle Ovington Boulevard
Uniondale, New York 11553
Tel. No. (516) 228-8484
Fax No. (516) 228-8516
ARP/ml

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.